









Markets
/
Stocks
/
nasdaq-carm
/

Carisma Therapeutics Inc

CARM

0.154USD

0.000

Close 11/04, 16:00（ET）Quotes delayed by 15 min

6.43MMarket Cap

LossP/E TTM



Carisma Therapeutics Inc

0.154

0.000

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Carisma Therapeutics Inc

Currency: USD Updated: 2025-10-10

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Carisma Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

165 / 502

Overall Ranking

274 / 4697

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

1.000

Target Price

+549.77%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Carisma Therapeutics Inc Highlights

StrengthsRisks

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.

Growing

The company is in a growing phase, with the latest annual income totaling USD 19.63M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 204.15.

Overvalued

The company’s latest PE is -0.13, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 8.28M shares, decreasing 39.69% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 329.29K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 7.35.

Financial Health

Currency: USD Updated: 2025-10-10

Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 12.44%.

Score

Industry at a Glance

Previous score

7.88

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Carisma Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-10-10

The company’s current valuation score is 6.98, which is equal to the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -0.13, which is 0.00% below the recent high of -0.13 and -19564.92% above the recent low of -25.56.

Score

Industry at a Glance

Previous score

6.98

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 165/502

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-10

The company’s current earnings forecast score is 7.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Carisma Therapeutics Inc is 1.00, with a high of 1.00 and a low of 1.00.

Score

Industry at a Glance

Previous score

7.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Buy

Current Rating

1.000

Target Price

+549.77%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Carisma Therapeutics Inc

CARM

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-10

The company’s current price momentum score is 5.42, which is lower than the Biotechnology & Medical Research industry's average of 6.83. Sideways: Currently, the stock price is trading between the resistance level at 0.31 and the support level at 0.07, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.09

Change

0.33

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(5)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.016

Sell

RSI(14)

29.985

Sell

STOCH(KDJ)(9,3,3)

27.412

Sell

ATR(14)

0.034

High Vlolatility

CCI(14)

-398.508

Oversold

Williams %R

95.701

Oversold

TRIX(12,20)

-0.951

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.243

Sell

MA10

0.257

Sell

MA20

0.276

Sell

MA50

0.291

Sell

MA100

0.328

Sell

MA200

0.344

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-10

The latest institutional shareholding proportion is 19.80%, representing a quarter-over-quarter decrease of 66.73%. The largest institutional shareholder is The Vanguard, holding a total of 350.32K shares, representing 0.84% of shares outstanding, with 75.33% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Modernatx Inc

5.06M

Longview Innovation Corp

2.71M

Wellington Partners Venture Capital GmbH

2.30M

SymBiosis Capital Management, LLC

2.22M

Abbvie Biotechnology Ltd

1.86M

-32.51%

Merck & Co Inc

1.47M

University of Pennsylvania Trustees

1.25M

Aju IB Investment Co., Ltd.

718.33K

The Vanguard Group, Inc.

Star Investors

350.32K

-74.90%

BlackRock Institutional Trust Company, N.A.

336.79K

-16.14%

Risk Assessment

Currency: USD Updated: 2025-10-10

The company’s current risk assessment score is 1.29, which is lower than the Biotechnology & Medical Research industry's average of 3.48. The company's beta value is 2.06. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.